The Companion Diagnostics (CDx) Market 2014-2024

コンパニオン診断(CDx)市場(2014-2024)

◆タイトル:The Companion Diagnostics (CDx) Market 2014-2024
◆商品コード:Visiongain-4052613
◆調査・発行会社:visiongain
◆発行日:2014年1月
◆ページ数:145
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single user licence(1名使用)GBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Dept Licence(部署内共有可)GBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site Licence(同一国内社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"コンパニオン診断(CDx)市場(2014-2024)"について調査・分析し、エグゼクティブサマリー、市場動向、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、市場環境分析、専門家の見解、主要企業分析、結論などの情報をお届けいたします。

Our new study shows you the commercial potential of companion diagnostics
What does the future hold for the companion diagnostics market? Visiongain’s brand new report shows you the potential revenues to 2024, assessing data, trends, opportunities and prospects there.
Our 145 page report provides 103 tables, figures and charts. Discover the most lucrative areas in the industry and the future market prospects. You will see financial results, interviews, trends, opportunities, and revenue predictions.
Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT), company profiles and commercial developments. Read full transcripts of two exclusive expert opinion interviews from leading industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Biomonitor A/S, Arsalan Kharazmi, PhD, CEO
- Ambry Genetics, Ardy Arianpour, MBA, Senior Vice President of Business Development

You will find prospects for key submarkets
Growth in this market will be fuelled by an increasing demand for safer and more efficacious medicines. In addition to analyses of the overall world market, you see revenue forecasting of two submarkets to 2024:
• Theranostics
• Other Companion Diagnostics
Our investigation shows business research and analysis with individual revenue forecasts and discussions.
Prospects for leading countries are shown to 2024
Events and progress worldwide will influence the market. Regulatory authorities mandating the approval of diagnostics simultaneously with therapies will propel the companion diagnostics market in the coming years.
You will discover individual revenue forecasts to 2024 for 9 leading national markets:
• US
• Japan
• UK
• Germany
• France
• Spain
• Italy
• China
• India
• RoW
Greater uptake of existing technology worldwide will also stimulate the industry and market.
Leading companies and potential for market growth
Overall world revenue for companion diagnostics will reach $3bn in 2014. M&A activity in the companion diagnostics market has experienced explosive growth in recent years. We expect this trend to continue as most pharmaceutical companies do not have an in-house diagnostic capability for either the development of a companion diagnostic or the commercialisation of the test once the drug is approved.
Our research profiles leading companies, assessing their technologies and products. You will see which technologies and organisations hold the greatest potential.
In particular, we profile these leading organisations:
• Roche
• Qiagen
• Myriad Genetics
• Siemens Diagnostics
• Abbott Molecular
• BioMérieux
• Danaher
In general, a company profile gives you the following information:
• Discussion of a company’s activities and outlook
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues affect the companion diagnostics market?
Our study lets you assess industry trends and outlooks. You will find discussions, including qualitative analyses:
• Reimbursement challenges
• Drive towards personalised medicine and support from regulatory authorities
• Increasing compliance and reduction of adverse reactions
• Increasing development and employment of biomarkers at earlier stages of development
• International expansion – targeting emerging national markets
• Complex business models and business partnerships
• Lack of clear regulatory guidelines
How The Companion Diagnostics (CDx) Market 2014-2024 report helps you
In summary, our report gives you the following knowledge:
• Revenues forecasts to 2024 for the overall world companion diagnostics market and 2 submarkets – discover that industry’s prospects, finding promising places for investments and revenues
• Assess 7 leading companies, and others, discovering activities and outlooks
• Market forecasting to 2024 for 9 key national markets: US, Japan, Germany, UK, France, Spain, Italy, China, India and RoW.
• View opinions from our survey, seeing two interviews with authorities
• Investigation of competition and opportunities influencing sales
• Discussion of what stimulates and restrains the industry and market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed on business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for companion diagnostics. You will find data, trends and predictions. Please order our report now.

【レポートの目次】

1. Executive Summary
1.1 Overview of Findings
1.2 Aims, Scope and Format of the Report
1.2.1 Chapter Outline
1.3 Research and Analysis Methods
2. Introduction to Companion Diagnostics
2.1 Companion Diagnostic Overview
2.2 What is Personalised Medicine?
2.3 In Vitro Diagnostics (IVD) and Targeted Therapies: The Core of Personalised Medicine
2.3.1 What are In Vitro Diagnostic (IVD) Tests?
2.3.2 How IVDs Help Provide Personalised Treatment
2.4 Companion Diagnostics: Tools for Personalised Medicine
2.4.1 Theranostics: A Subset of Companion Diagnostics
2.5 Biomarkers to Companion Diagnostics
2.5.1 Genomic Biomarkers
2.5.2 Genomic Biomarkers in Oncology
2.6 Development of Companion Diagnostics
3. The World Companion Diagnostics Market 2014-2024
3.1 Scope and Limitations
3.2 The World Companion Diagnostics Market 2012-2013
3.3 Sales Forecast for Global Companion Diagnostics Market, 2014-2024
3.4 Companion Diagnostics is One of the Fastest Growing Segments in the IVD Market
3.4.1 Companion Diagnostics Gaining Greater Share of the IVD Market
3.5 Breakdown of the Companion Diagnostics Market by Segment
3.6 How Fast will the Theranostics Market Grow to 2024?
3.6.1 Theranostics Gaining Greater Share of the Companion Diagnostics Market
4. Leading National Markets for Companion Diagnostics 2014-2024
4.1 Leading National Markets for Companion Diagnostics
4.1.2 Leading National Markets for Companion Diagnostics: Market Forecast 2014-2024
4.2 The US Companion Diagnostic Market 2014-2024
4.2.1 The US Continues to be the Largest Market
4.3 The Japanese Companion Diagnostics Market 2014-2024
4.4 The EU5 Markets Forecast 2014-2024
4.4.1 Companion Diagnostics Trends in the EU5 Markets
4.4.2 The German Companion Diagnostic Market 2014-2024
4.4.3 The French Companion Diagnostic Market 2014-2024
4.4.4 The Italian Companion Diagnostics Market 2014-2024
4.4.5 The Spanish Companion Diagnostics Market 2014-2024
4.5.6 The UK Companion Diagnostics Market 2014-2024
4.5 The Chinese Companion Diagnostics Market 2014-2024
4.6 The Indian Companion Diagnostics Market 2014-2024
5. Competitive Environment and Current Business Models in the Companion Diagnostics Market
5.1 Competitive Landscape 2012-2013
5.2 Stakeholders in the Companion Diagnostics Market
5.2.1 Regulatory Authorities
5.2.2 Testing Laboratories
5.2.3 Physicians and Patients
5.2.4 Payers
5.3 Business Models for the Development of Companion Diagnostics
5.4 Market for Companion Diagnostics: Small, but Growing
5.5 A Complex Market with Multiple Regulatory Pathways
5.6 Oncology is the Leading Indication for the Development of Companion Diagnostics
5.7 Factors Driving Companies to Enter the Companion Diagnostics Market
5.7.1 Regulatory Authorities Promoting the Development of Companion Diagnostics
5.7.2 Benefits of Employing Companion Diagnostics: Perspective of Pharmaceutical and
Diagnostic Companies
5.8 Companies in the Companion Diagnostics Market
5.8.1 Companies in the Companion Diagnostics Market: Developing Products and Providing
Services
5.8.2 Few Pharmaceutical Companies Have Dedicated Diagnostics Units
5.8.3 Collaborating with Pharmaceuticals: A Win-Win for Diagnostic Companies
6. Leading Companies in the Companion Diagnostic Market
6.1 Roche: Leaders in Companion Diagnostics
6.1.1 Sales and Recent Performance Analysis, 2012-2013
6.1.2 Roche Diagnostics by Region, 2012
6.1.3 Pipeline Drugs
6.1.4 Roche’s Growing Portfolio of Companion Diagnostics
6.2 Qiagen: Growing on the Partnership Model
6.2.1 Sales and Recent Performance Analysis, 2012
6.2.2 Qiagen’s Strategy for the Future
6.2.3 Provider of Choice for Molecular Companion Diagnostics
6.2.4 New Products on Qiagen’s list
6.3 Myriad Genetics
6.3.1 Sales and Recent Performance Analysis, Myriad Genetics
6.3.2 Myriad Genetics’ M&A Activity and Recent Partnerships
6.3.2.1 Acquisition of Myriad RBM
6.3.2.2 Myriad RBM
6.3.2.3 Strategic Debt Investment in Crescendo Bioscience
6.3.2.4 Agreement with Cephalon
6.3.2.5 Agreement with Tesaro
6.3.2.6 Agreement with PharmaMar
6.3.3 New Growth Opportunities
6.4 Siemens Diagnostics
6.4.1 Siemens Healthcare Research and Development for Diagnostics
6.4.2 Outperforming the Market
6.4.3 Siemens Partnerships
6.4.3.1 Partnership with ViiV Healthcare
6.4.3.2 Partnership with Tocagen
6.4.3.3 Collaboration with Janssen Pharmaceutical
6.5 Abbott Molecular
6.5.1 Sales and Recent Performance Analysis, 2012
6.5.2 Recent M&A Activity and Strategic Collaborations
6.5.2.1 Collaboration with GSK
6.5.2.2 Collaboration with Merck
6.5.2.3 Acquisition of STARLIMS Technologies
6.5.2.4 Acquisition of Ibis Biosciences, Inc.
6.6 BioMérieux
6.6.1 Recent M&A Activity and Collaborations
6.6.1.1 Partnership with GSK
6.6.1.2 Partnership with Ipsen
6.6.1.3 Partnership with Institute Merieux and Institute Pasteur
6.6.1.4 Collaboration with Hospices Civils de Lyon
6.6.1.5 Acquisition of ARGENE
6.6.1.6 Equity Interest in Knome, Inc.
6.6.1.7 Partnership with Thermo Fisher Scientific Inc.
6.6.1.8 Partnership with Genome Institute
6.6.1.9 Exclusive rights to Quanterix’s Simoa
6.7 Danaher
6.7.1 Sales and Recent Performance Analysis, 2012
6.7.2 Danaher’s Acquisitions
6.7.2.1 Acquisition of Leica Microsystems
6.7.2.2 Acquisition of Vision Systems
6.7.2.3 Acquisition of Genetix
6.7.2.4 Acquisition of Beckman Coulter
6.7.2.5 Acquisition of Iris International and Aperis Technologies
7. SWOT Analysis of the Companion Diagnostics Market
7.1 Introduction
7.2 Strengths
7.2.1 Maximising Benefits to Healthcare Stakeholders
7.2.2 Helps Stratify Patient Population on the Basis of Safety and Effectiveness
7.2.3 Increasing Signals from Regulators of Support for Companion Diagnostics
7.2.4 Increasing Compliance
7.2.5 Reduce Adverse Drug Reactions
7.2.6 Reducing the Cost of Healthcare
7.3 Opportunities
7.3.1 Fast Growing Emerging Markets
7.3.2 Many New partnerships and Business Models
7.3.3 Emerging therapeutic Areas in the Market
7.3.4 Reviving Failed or Withdrawn Drugs
7.3.5 Many Oncology Drugs in Pipeline with Companion Diagnostics
7.4 Weaknesses
7.4.1 Reimbursement Challenges for Diagnostic Companies
7.4.2 Lack of Clear Regulatory Guidelines on Companion Diagnostics
7.4.3 Unpredictable Clinical Efficacy of Companion Diagnostic
7.4.4 Difficult Development Coordination
7.5 Threats
7.5.1 Complex Business Models and Business Partnerships
8. Expert Opinion
8.1 Interview with Arsalan Kharazmi, Ph.D, CEO of Biomonitor A/S
8.1.1 The Importance of Cell-Based Assays as a Companion Diagnostic Test
8.1.2 The Potential Growth of the Theranostics Market
8.1.3 The Potential in Emerging Markets
8.1.4 The Business Model for Theranostics
8.1.5 The Competitive Landscape for Companion Diagnostics
8.2 Interview with Ardy Arianpour, MBA, Senior Vice President of Business Development at Ambry Genetics
8.2.1 The Future for Companion Diagnostics
8.2.2 The Business Model for Companion Diagnostic Market
8.2.3 The Challenges in Companion Diagnostics
9. Conclusions
9.1 Overview
9.2 Prominent Companies in the Market
9.3 Companion Diagnostics Are Changing the Traditional Pharmaceutical Model
9.4 Commercial Drivers of the Companion Diagnostics Market
9.5 Personalised Medicine is a Strong Driver of the Theranostics Sector
9.6 Emerging Markets
9.7 Commercial Restraints in the Companion Diagnostics Market
9.8 Targeted Therapies Are Revolutionising the Current Model of Pharmaceutical R&D
9.9 Future Outlook and Concluding Remarks



List of Tables
Table 2.1 Differences Between Traditional & Personalised Medicine, 2013
Table 2.2 List of Approved Drugs Paired with a Companion Diagnostic, 2012-2013
Table 2.3 Examples of Clinically Relevant Cancer Biomarkers
Table 3.1 World In Vitro Diagnostics Market: Revenues ($bn) and Market Share (%) by Segment, 2012
Table 3.2 World Companion Diagnostics Market: Revenues ($bn), AGR (%), CAGR (%), 2012-2017
Table 3.3 World Companion Diagnostics Market: Revenues ($bn), AGR (%), CAGR (%), 2018-2024
Table 3.4 Market Shares (%) of Companion Diagnostics in the IVD Market, 2012, 2017 & 2024
Table 3.5 World Companion Diagnostics Market: Revenues ($bn) and Market Shares (%) by Segment, 2012
Table 3.6 World Companion Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Segment. 2012-2017
Table 3.7 World Companion Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Segment. 2018-2024
Table 3.8 Market Shares (%) of Theranostics in the Companion Diagnostics Market in 2012, 2017 & 2024
Table 4.1 The Leading National Markets for Companion Diagnostics ($m), 2012
Table 4.2 The Leading National Companion Diagnostics Market Forecast : Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.3 The Leading National Companion Diagnostics Market Forecast : Revenues ($m), AGR (%), CAGR (%), 2018-2024
Table 4.4 The US Companion Diagnostics Market Forecast : Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.5 The US Companion Diagnostics Market Forecast : Revenues ($m), AGR (%), CAGR (%), 2018-2024
Table 4.6 The Japanese Companion Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.7 The Japanese Companion Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2024
Table 4.8 EU5 Companion Diagnostic National Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.9 EU5 Companion Diagnostic National Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2018-2024
Table 4.10 The German Companion Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.11 The German Companion Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2024
Table 4.12 The French Companion Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.13 The French Companion Diagnostics Market Forecast :Revenues ($m), AGR (%), CAGR (%), 2018-2024
Table 4.14 The Italian Companion Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.15 The Italian Companion Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2024
Table 4.16 The Spanish Companion Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.17 The Spanish Companion Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2024
Table 4.18 The UK Companion Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.19 The UK Companion Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2024
Table 4.20 The Chinese Companion Diagnostics Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.21 The Chinese Companion Diagnostics Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2018-2024
Table 4.22 The Indian Companion Diagnostics Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.23 The Indian Companion Diagnostics Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2018-2024
Table 5.1 Growth of Companion Diagnostics: Benefits for Pharmaceutical and Diagnostic Companies, 2013
Table 5.2 List of Other Companies in the Companion Diagnostics Market, 2013_Toc374969885
Table 6.1 Roche: Revenue ($bn) and Revenue Shares (%) by Sector, 2012
_Toc374969887Table 6.2 Roche Diagnostics: Revenue ($bn) and Revenue Shares (%), by Region 2012
Table 6.3 Roche Diagnostics: List of Selected Products with an In-house Companion Diagnostic Drug Program
Table 6.4 Roche Diagnostics: List of Marketed Companion Diagnostics, 2013
Table 6.5 Qiagen: Sales ($m) by Business Sector, 2012
Table 6.6 Myriad Genetics: Revenue ($m), and Shares (%) by Sector, 2012
Table 6.7 Myriad Genetics: Revenue ($m), Revenue Share (%), Percentage Change (%) by Product, 2011-2012
Table 6.8 Myriad Genetics: Biomarker Product Portfolio, 2013
Table 6.9 Siemens Diagnostics: Ranking (#) by Sector, 2011
Table 6.10 Abbott Molecular: Diagnostics Sales ($m) by Division in the US and Internationally, 1Q13
Table 6.11 Biomérieux: Revenues Sales ($m), Percentage Change (%) by Region, 2011-2012
Table 6.12 Danaher: Revenue Shares (%) by Segment, 2010-2012
Table 6.13 Danaher Life Sciences and Diagnostics: Revenue Shares (%) by Region, 2012
Table 7.1 SWOT Analysis of the Companion Diagnostics Market, 2012-2024
Table 7.2 Average Response Rates to Treatment for Various Diseases, 2013
Table 7.3 Drugs Metabolised by CYP450: 2C19 and 2D6, 2012
Table 7.4 List of Recent Companion Diagnostics Partnerships, 2013
Table 9.1 Theranostics and Other Diagnostics: World Sales Forecast ($bn), 2012, 2017, and 2024
List of Figures
Figure 2.1 The Pillars of Personalised Medicine
Figure 2.2 Type of Companion Diagnostics on the Basis of Purpose/Use, 2012
Figure 2.3 Development of Biomarkers into Companion Diagnostics, 2013
Figure 3.1 World Companion Diagnostics Market Share (%) in the IVD Market, 2012
Figure 3.2 World IVD and Companion Diagnostics Market: Sales Forecast ($bn), 2012-2024
Figure 3.3 World Companion Diagnostics Market and IVD Market Forecast: AGRs (%), 2013-2024
Figure 3.4 World Companion Diagnostics Market Share (%) in the IVD Market, 2017
Figure 3.5 World Companion Diagnostics Market Share (%) in the IVD Market, 2024
Figure 3.6 World Companion Diagnostics Market: Market Shares (%) by Segment, 2012
Figure 3.7 World Companion Diagnostics Sub-Markets: Sales Forecasts ($bn), 2012-2024
Figure 3.8 Companion Diagnostics Market Shares (%) by Sector in the IVD Market, 2012
Figure 3.9 World Theranostics Market Share (%) in the Companion Diagnostics Market, 2012
Figure 3.10 Market Shares (%) of Theranostics in the Companion Diagnostics Market, 2017
Figure 3.11 Market Shares (%) of Theranostics in the Companion Diagnostics Market, 2024
Figure 4.1 The Leading National Markets for Companion Diagnostics by Market Share (%), 2012
Figure 4.2 The Companion Diagnostics Market Forecast: Revenues ($m) by Region, 2012-2017
Figure 4.3 The Companion Diagnostics Market Forecast: Revenues ($m) by Region, 2018-2024
Figure 4.4 The US Companion Diagnostics Market Forecast ($m), 2012-2024
Figure 4.5 The Japanese Companion Diagnostics Market Forecast ($m), 2012-2024
Figure 4.6 The EU5 Companion Diagnostics Market Forecast ($m) by Country, 2012-2024
Figure 4.7 EU5 Market Breakdown by Country: Market Shares (%), 2012
Figure 4.8 The German Companion Diagnostics Market Forecast ($m), 2012-2024
Figure 4.9 The French Companion Diagnostics Market Forecast ($m), 2012-2024
Figure 4.10 The Italian Companion Diagnostics Market Forecast ($m), 2012-2024
Figure 4.11 The Spanish Companion Diagnostics Market Forecast ($m), 2012-2024
Figure 4.12 The UK Companion Diagnostics Market Forecast ($m), 2012-2024
Figure 4.13 The Chinese Companion Diagnostics Market Forecast ($m), 2012-2024
Figure 4.14 The Indian Companion Diagnostics Market Forecasts ($m), 2012-2024
Figure 5.1 Stakeholders in the Companion Diagnostics Market, 2013
Figure 5.2 Current Business Models for the Development of Companion Diagnostics, 2012
Figure 6.1 Roche: Revenue Shares (%) by Sector, 2012
Figure 6.2 Roche: Revenues ($bn) by Sector, 2012
Figure 6.3 Roche: Revenues ($bn) by Sector, 1Q 2013
Figure 6.4 Qiagen: Revenue ($m), Net Income ($m) and Profit Margin (%), 2008-2012
Figure 6.5 Myriad Genetics: Historical Net Revenues ($m), 2005-2012
Figure 6.6 Myriad Genetics: Revenue Shares (%) by Product , 2012
Figure 6.7 Siemens Diagnostics: Profit ($m), 2011-2012
Figure 6.8 Abbott Molecular Diagnostic: Historical Sales ($m), 2010-2012
Figure 6.9 Abbott Laboratories: Sales (%), by Division, 2012
Figure 6.10 BioMeriéux: Sales ($m), 2011-2012
Figure 6.11 Biomeriéux: Sales by Region (%), 2012
Figure 6.12 Biomeriéux: Sales by Region ($m), 2012
Figure 6.13 Danaher Life Sciences and Diagnostics: Revenue Shares (%) by Region, 2012
Figure 7.1 Average Response Rates (%) for Various Diseases, 2013
Figure 7.2 Number of Companion Diagnostics Partnering by Therapeutic Area Since 2007
Figure 7.3 Developing Oncology Drugs Breakdown by Biomarker (%)
Figure 9.1 Companion Diagnostics Market: World Sales Forecast ($bn), 2012, 2017, and 2024
Figure 9.2 Theranostics and Other Diagnostics: World Sales Forecast ($bn), 2012, 2017, and 2024
Figure 9.3 Companion Diagnostics Market Forecast: AGRs (%) in India, China and Global Market, 2012-2024


【掲載企業】

Abbott Molecular
Agendia
Alacris Theranostics GmbH
AltheaDx
Ambry Genetics
Amgen
ARGENE
ARIAD Pharmaceuticals
Astellas
AstraZeneca
Beckman Coulter
BioMérieux
Biomonitor
Boehringer Ingelheim
Brain Resource Company
Bristol-Myers Squibb
CancerGuide Diagnostics
Caprion Proteomics
Caris Life Sciences
Celera (acquired by Quest Diagnostics in May 2011)
Cell Signalling Technologies
Cephalon
Cepheid
ChemGenex Pharmaceuticals
Clinical Reference Laboratory
CompanDx
Crescendo Bioscience
Curidium Medica
Cytyc Corporation
Dako
Danaher
DiagnoCure
Dx assays
DxS
Eli Lilly
Endocyte
Exosome Diagnostics
Flagship Biosciences
Foundation Medicine
Genentech
Genetix
Genfit
GenMark Diagnostics
Genome Institute
Genomic Health
GSK
Hatteras Venture Partners
HistologiX
Hospices Civils de Lyon
Ibis Biosciences, Inc.
ImCloneSystems
InDex Pharmaceuticals
Institute Merieux
Institute Pasteur
Intersouth Partners
Inverness Medical Innovations
Invivoscribe
Ipsen
Ipsogen
Iris International and Aperis Technologies
Janssen Pharmaceutical
Kimball Genetics (a division of LabCorp)
Knome, Inc
Lab21
Laboratory for Personalized Molecular Medicine
Leica
Leica Microsystems
Life Technologies
Merck
Molecular MD
Myriad Genetics
Myriad RBM
Nanosphere
Novartis
Opko Health
OSI Pharmaceuticals
Oxford BioTherapeutics (earlier Oxford Genome Sciences)
Pfizer
PharmaMar
Progenika Biopharma
Prometheus
Qiagen
Quanterix
Quintiles Transnational Corporation
Randox Pharma Services
RAS Lifesciences Pvt. Ltd (RAS)
RiboMed Biotechnologies
Roche Molecular Systems
Rules-Based Medicines Inc.
Saladax Biomedical
Siemens
Signal Genetics
Sirius Genetics
Skyline Diagnostics
STARLIMS technologies
Takeda
Target Discovery
TcLand Expression
Telegraph Hill Partners
Tesaro
Teva Pharmaceutical Industries
Theranostics (NZ)
Theranostics Health
Thermo Fisher Scientific Inc.
Third Wave Technologies (a wholly owned subsidiary of Hologic)
TIB MolBiol
Tocagen
Tragara Pharmaceuticals
Transgene
Transgenomic
TrimGen Corporation
Unilabs
Ventana Medical Systems
ViiV Healthcare
Vision Systems
Weisenthal Cancer Group
Zinfandel
Other Organisations Mentioned in This Report
Cancer Research UK
Columbia University
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
Haute Autorité de Santé (HAS)
Medical Research Council
National Health Service (NHS)
National Institute for Health and Care Excellence (NICE)
National Institutes of Health (NIH)
ServizioSanitarioNazionale (SSN)
The Association of British Pharmaceutical Industries (ABPI)
Tufts Center for the Study of Drug Development


★調査レポート[コンパニオン診断(CDx)市場(2014-2024)] ( The Companion Diagnostics (CDx) Market 2014-2024 / Visiongain-4052613) 販売に関する免責事項
[コンパニオン診断(CDx)市場(2014-2024)] ( The Companion Diagnostics (CDx) Market 2014-2024 / Visiongain-4052613) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆